Arrowhead (ARWR) announced that it has earned a $200M milestone payment from Sarepta (SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference therapeutic for the treatment of type 1 myotonic dystrophy, the most common adult-onset muscular dystrophy. In accordance with the license and collaboration agreement with Sarepta, Arrowhead expects to receive this payment within 60 days. The second milestone event was reached following a drug safety committee review, subsequent authorization to dose escalate, and achievement of a pre-specified patient enrollment target. Accrual of patients in cohort 4 of the multiple ascending dose portion of the study is nearly complete and the company intends to initiate enrollment in cohort 5 in the first quarter of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Options Volatility and Implied Earnings Moves This Week, November 24 – November 26, 2025
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 Earnings Cheat Sheet
- Arrowhead price target raised to $48 from $27 at Goldman Sachs
- Arrowhead price target raised to $52 from $45 at RBC Capital
- Arrowhead price target raised to $70 from $45 at Piper Sandler